Company news

Invex Therapeutics Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

First Australian Site Activated in IIH EVOLVE Phase 3

October 23, 2022

Second HREC Approval for IIH EVOLVE Phase III Clinical Trial

September 29, 2022

4E and Annual Report to shareholders

August 18, 2022

Invex receives IND approval

August 18, 2022

Quarterly Activities/Appendix 4C Cash Flow Report

July 5, 2022

HREC and TGA Approval to Commence Phase 3 in Australia

July 3, 2022

Invex Receives UK Approval to Commence Phase III Trial

June 28, 2022

Half Yearly Report and Accounts

February 22, 2022

New Executive Director and Chairman Agreements

January 30, 2022

Appointment IIH EVOLVE Phase III Trial Steering Group Chair

December 16, 2021

Invex Therapeutics: Chairman's Address to Shareholders at AGM

November 25, 2021

Global Phase 3 Trial of Presendin to Launch in Q4 2021

November 3, 2021

Notice of Investor Call and Presentation

September 27, 2021

Exclusive Collaboration and Manufacturing Agreement

September 27, 2021

Appendix 4E and Annual Report

August 26, 2021

Invex Granted Key European Patent for Exenatide

August 16, 2021

Invex Receives Written Response from FDA on Type C Meeting

June 14, 2021

Invex Granted Type C Meeting with FDA

April 21, 2021

Appendix 4C - quarterly

April 12, 2021

Invex Successfully Concludes Protocol Assistance with EMA

December 22, 2020

Chairmans Address to Shareholders and Presentation

November 18, 2020

Investor Presentation

November 4, 2020

Invex Provides Development Update

October 30, 2020

Quarterly Report and Appendix 4C with appendix

August 7, 2020

Quarterly Report and Appendix 4C

July 23, 2020

Initial FDA and EMA Advice on Presendin Development

July 22, 2020

Notice of Allowance for Key US Exenatide Patent

July 20, 2020

Phase II Clinical Results and Capital Raising Presentation

May 22, 2020

Succesful $26 million Share Placement

May 22, 2020

Exenatide Meets Key Endpoints in IIH Clinical Trial

May 19, 2020

Appendix 4D and Half-year Report

February 26, 2020

Phase II Recruitment Completed

October 14, 2019

Japanese Patent Granted

October 7, 2019

Preliminary Final Report

August 27, 2019

← Newer news releases

Decks

The 5 newest of 16 decks. Every deck is listed under its year.